TWI327564B - New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it - Google Patents
New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it Download PDFInfo
- Publication number
- TWI327564B TWI327564B TW095128301A TW95128301A TWI327564B TW I327564 B TWI327564 B TW I327564B TW 095128301 A TW095128301 A TW 095128301A TW 95128301 A TW95128301 A TW 95128301A TW I327564 B TWI327564 B TW I327564B
- Authority
- TW
- Taiwan
- Prior art keywords
- agomelatine
- disorders
- pharmaceutical composition
- crystalline form
- doc
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims description 10
- 229960002629 agomelatine Drugs 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 9
- 238000000034 method Methods 0.000 title description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003987 melatonin Drugs 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000035882 stress Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 231100000216 vascular lesion Toxicity 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 3
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 3
- 208000012672 seasonal affective disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 208000027559 Appetite disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229910000420 cerium oxide Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- NSZDTGXTVPOMIJ-UHFFFAOYSA-N C(CCCCCCCCC)OC1=CC=C2C=CC=C(C2=C1)CCNC(C)=O Chemical compound C(CCCCCCCCC)OC1=CC=C2C=CC=C(C2=C1)CCNC(C)=O NSZDTGXTVPOMIJ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Description
1327564 九、發明說明： 【發明所屬之技術領域】 本發明係關於一種如式（I)之阿戈美拉汀或N-[2-(7-甲氧 基-1-萘基）乙基]乙酿胺之新晶形IV :
其製備方法及包含其之醫藥組合物。 【先前技術】 阿戈美拉汀或N-[2-(7-曱氧基-1-萘基）乙基]乙醯胺具有 重要之藥理性質。 其瑞實具有雙重特徵’一方面為褪黑激素能系統受體之 激動劑，及另一方面為5-HT2c受體之拮抗劑《此等性質在 中樞神經系統中及尤其在嚴重抑鬱症、季節性情感障礙 症、睡眠障礙、心血管病變、消化系統病變、失眠症及由 時差產生之疲勞、食您障礙及肥胖之治療中賦與活性a 阿戈美拉汀，其製備及其治療用途在歐洲專利說明書Ep 〇 447 285中已有所描述。 鑒於此化合物之醫藥價值，能夠獲得具有極高純度、具 有適當界定之晶形，較佳可再現之該化合物是很重要的， 其用調配物來展示重要特徵且充分穩定以允許其長期存儲 而對溫度、光、濕度或氧含量無特別要求。 專利說明書EP 0 447 285從7_甲氧基·丨_四氫萘酮開始， H3098.doc 1327564 以八個步驟描述阿戈美拉汀之製備。然而，彼文獻並未以 可再現方式規定用於獲得以展示彼等特徵之形式之阿戈美 拉汀的條件" 【發明内容】 申請者現已開發一種新的合成方法，其允許獲得以適當 界定、較佳可再現、尤其對於調配物展現出重要特徵之晶 形之阿戈美拉汀。 更特定言之，本發明係關於式⑴之化合物之晶形ιν，其 由以下粉末X射線繞射圖表表徵、用Siemens D5005繞射計 (銅對陰極）量測及以内部平面距離d、布拉格（Bragg's)角度 2Θ、強度及相對強度（表示成最大強度射線之百分比）來表 示： 2-θ(°) 指數 d(A) 指數 強度 (%) 5.04 17.524 8 10.16 8.703 68 10.51 8.409 9 15.22 5.818 28 16.75 5.288 39 17.41 5.089 60 18.03 4.915 100 18.81 4.714 71 20.48 4.333 37 21.61 4.110 16 23.27 3.819 11 24.04 3.699 26 24.27 3.665 42 24.77 3.591 24 25.57 3.481 13 27.06 3.292 6 27.95 3.190 11
H3098.doc 1327564 本發明亦係關於一種製備式⑴之化合物之晶形IV的方 法，該方法之特徵在於將阿戈美拉汀於l1(rc加熱直到完 全熔化’及接著於50與70°c間迅速冷卻及在70。(：保持約5 小時直至結晶。 獲得彼晶形之優勢在於其允許製備具有一致及可再現之 組合物之醫藥調配物，其特別有利於當該醫藥調配物用於 口服投藥時。 對如此獲得之形態1V之藥理研究已表明其關於中枢神經 系統及關於微循環具有實質活性，使得其得以證實阿戈美 拉>丁之晶形IV對於治療精神緊張、睡眠障礙、焦慮症、嚴 重抑鬱症、季節性情感障礙、心企管病變、消化系統病 變、失眠症及由於時差所引起之疲勞、精神分裂症、恐慌 發作、憂鬱症、食慾障礙、肥胖、失眠症、疼痛、精神性 失常、癲癇症、糖尿病、帕金森氏症、老年癡呆症、與正 常或病理性衰老相關之各種失調症、偏頭痛、記憶力喪 Φ 失、阿茲海默氏病症及大腦循環失調症有效。在另一活性 方面，表明阿戈美拉、;I之晶形IV可用於治療性功能障礙、 其具有抑制排即及免疫調節之性質、及其適合用於治療癌 症。 阿戈美拉汀之晶形IV較佳用於治療嚴重抑鬱症、季節性 情感障礙、睡眠障礙、心血管病變、失眠症及由時差引起 之疲勞、食慾障礙及肥胖。
本發明亦係關於醫藥組合物，苴由紅A A 再包括作為活性成份之阿 戈美拉汀之晶形1v連同一或多種合摘沾 里σ週的惰性、無毒之賦形 113098.doc 1327564 劑。根據本發明之醫藥組合物中，提到，尤其適於口服、 非經腸（靜脈内或皮下）或鼻腔投藥之醫藥組合物、錠劑或 糖衣藥丸、顆粒、舌下錠、明膠膠囊、口含劑、栓劑、乳 劑、軟膏劑、皮凝膠、注射製劑、飲用懸浮液及可崩解糊 劑。 可根據失調症之性質及嚴重性、投藥路徑及患者之年齡 及體重調整有效劑量。在一或多次投藥過程中，劑量以每 天自0.1 mg至1 g變化。 【實施方式】 以下實例說明但不以任何方式限制本發明。
實例1 : Ν-[2·(7·甲氧基-1-萘基）乙基】乙醯胺之晶形IV 將100 g N-[2-(7-甲氧基-i_萘基）乙基]乙醯胺於11〇。〇加 熱直到完全熔化，及接著於50至7〇〇c間迅速冷卻，及在 70°C保持5小時直至結晶。所獲得之晶形IV由以下粉末χ射 線繞射圖表表徵、用Siemens D5005繞射計（銅對陰極）量測 及以内部平面距離d、Bragg、角度2Θ、強度及相對強度（表 示成最大強度射線之百分比）來表示： 113098.doc 9- 2-θ(°) 指數 d(A) 指數 強度 (%) 5.04 17.524 8 10.16 8.703 68 10.51 8.409 9 15.22 5.818 28 16.75 5.288 39 17.41 5.089 60 18.03 4.915 100 18.81 4.714 71 20.48 4.333 37 21.61 4.110 16 23.27 3.819 11 24.04 3.699 26 24.27 3.665 42 24.77 3.591 24 25.57 3.481 13 27.06 3.292 6 27.95 3.190 11 1327564 實例2 :醫藥組合物 製備1000粒錠劑之調配物，每粒錠劑包含之劑量為25 mg : 實例1之化合物..............................................25 g 乳糖單水合物................................................62 g 硬脂酸鎂...................................................... 1.3 g 玉米澱粉......................................................26 g 麥芽糊精...................................................... 9 g 無水膠狀二氧化矽......................................... 0.3 g A型羥基乙酸澱粉鈉....................................... 4 g 硬脂酸......................................................... 2.6 g 113098.doc 10- 1327564 實例3 :醫藥組合物 製備1000粒錠劑之調配物，每粒錠劑包含之劑量為25 mg : 實例1之化合物...............................................25 g 乳糖單水合物.................................................62 g 硬脂酸鎂....................................................... 1.3 g 聚乙烯吡咯酮................................................. 9 g 無水膠狀二氧化矽...........................................0.3 g 纖維素羥乙酸鈉...............................................30 g 硬脂酸............................................................2.6 g
113098.doc •11·
Claims (1)
1327564 公告本 十、申請專利範圍： 1. 一種式（I)之阿戈美拉汀之晶形IV
NHCOMe MeO
(I)
其由以下粉末X射線繞射圖表表徵，用一繞射計（銅對陰 極）量測及以内部平面距離d、布拉格（Bragg's)角度2Θ、 強度及相對強度（表示成最大強度射線之百分比）來表 示： 2-θ(°) 指數 d(A) 指數 強度 (%) 5.04 17.524 8 10.16 8.703 68 10.51 8.409 9 15.22 5.818 28 16.75 5.288 39 17.41 5.089 60 18.03 4.915 100 18.81 4.714 71 20.48 4.333 37 21.61 4.110 16 23.27 3.819 11 24.04 3.699 26 24.27 3.665 42 24.77 3.591 24 25.57 3.481 13 27.06 3.292 6 27.95 3.190 11 2. 一種製備如請求項1之式⑴之化合物之晶形IV的方法， 其特徵在於將阿戈美拉汀於110°C加熱直到完全熔化，及 接著於50與70°C間迅速冷卻，及在70°C保持約5小時直至 結晶。 113098.doc 1327564 3· 一種醫藥組合物，其包含作為活性成份之如請求項1之 阿戈美拉汀之晶形IV，與—或多種醫藥上可接受之惰 性、無毒载劑組合。 4. 如明求項3之醫藥組合物，其用於製造一治療褪黑素能 失調症之藥劑。 5. 如清求項3之醫藥組合物，其用於製造治療睡眠障礙、 精神緊張、焦慮症、#節性情感障礙或嚴重抑f症、心
血管病變、消化系統病變、失眠症及由於時差所引起的 疲勞精神分裂症、恐慌發作、憂鬱症、食您障礙、肥 胖、失眠症、精神性失常、癲癇症、糖尿病、帕金森氏 症、老年癡呆症 '與正常或病理性衰老相關之各種失調 症、偏頭痛、記憶力喪失、阿兹海默氏病症、大腦循環 =二治療性功能障礙、作為排即抑制劑、免疫調 卽劑及癌症之藥劑。
113098.doc
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508277A FR2889522B1 (fr) | 2005-08-03 | 2005-08-03 | Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200736198A TW200736198A (en) | 2007-10-01 |
| TWI327564B true TWI327564B (en) | 2010-07-21 |
Family
ID=36589248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095128301A TWI327564B (en) | 2005-08-03 | 2006-08-02 | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1752444A1 (zh) |
| JP (1) | JP4580371B2 (zh) |
| CN (1) | CN100445264C (zh) |
| AR (1) | AR057714A1 (zh) |
| AU (1) | AU2006203340B2 (zh) |
| BR (1) | BRPI0603043A (zh) |
| CA (1) | CA2555119A1 (zh) |
| CO (1) | CO5780132A1 (zh) |
| EA (1) | EA010867B1 (zh) |
| FR (1) | FR2889522B1 (zh) |
| GE (1) | GEP20094577B (zh) |
| GT (1) | GT200600345A (zh) |
| HK (1) | HK1098129A1 (zh) |
| MA (1) | MA28450B1 (zh) |
| MX (1) | MXPA06008693A (zh) |
| MY (1) | MY141306A (zh) |
| NO (1) | NO20063518L (zh) |
| NZ (1) | NZ548863A (zh) |
| PE (1) | PE20070242A1 (zh) |
| SA (1) | SA06270254B1 (zh) |
| SG (1) | SG130111A1 (zh) |
| TW (1) | TWI327564B (zh) |
| UA (1) | UA83718C2 (zh) |
| WO (1) | WO2007015002A2 (zh) |
| ZA (1) | ZA200606455B (zh) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2923482B1 (fr) * | 2007-11-09 | 2010-01-29 | Servier Lab | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2934856B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede d'obtention de la forme cristalline v de l'agomelatine |
| CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
| WO2011006387A1 (zh) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法 |
| CN102001959B (zh) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
| CN102050755B (zh) * | 2009-10-29 | 2014-11-05 | 重庆医药工业研究院有限责任公司 | 阿戈美拉汀的晶型及其制备方法 |
| CN101781226B (zh) | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀及其药物组合物 |
| CN101870662B (zh) * | 2010-05-21 | 2013-03-20 | 中山大学 | 结晶型阿戈美拉汀溶剂化物及其制备方法 |
| CL2011001405A1 (es) | 2010-06-10 | 2012-03-30 | Gador S A Conicet | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. |
| CN102690210A (zh) | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
| CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
| FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| CN102503886B (zh) * | 2011-10-11 | 2013-09-11 | 中山大学 | 阿戈美拉汀-异烟碱共晶及其组合物和制备方法 |
| ES2634243T3 (es) | 2011-11-30 | 2017-09-27 | Ratiopharm Gmbh | Complejo de agomelatina-urea y formas cristalinas del mismo |
| CZ2012108A3 (en) | 2012-02-15 | 2013-02-27 | Zentiva Ks | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
| CN102643208B (zh) * | 2012-04-14 | 2013-11-06 | 中山大学 | 一种阿戈美拉汀ⅰ晶型的制备方法 |
| WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
| FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| PT2810656T (pt) | 2013-06-06 | 2017-11-13 | Zentiva As | Formulações de agomelatina compreendendo agomelatina na forma de cocristais |
| EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| CZ2013621A3 (cs) | 2013-08-13 | 2015-02-25 | Zentiva, K.S. | Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci |
| WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
| EP3075724B1 (en) | 2015-03-31 | 2023-07-12 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Solid form of agomelatine |
| EP3466413A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
| EP3466923A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Process for the preparation of agomelatine in crystalline form |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2866335B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| FR2866336B1 (fr) * | 2004-02-13 | 2006-03-24 | Servier Lab | Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine |
-
2005
- 2005-08-03 FR FR0508277A patent/FR2889522B1/fr not_active Expired - Fee Related
-
2006
- 2006-07-19 PE PE2006000867A patent/PE20070242A1/es not_active Application Discontinuation
- 2006-07-24 MA MA29211A patent/MA28450B1/fr unknown
- 2006-07-31 CO CO06074815A patent/CO5780132A1/es not_active Application Discontinuation
- 2006-07-31 GT GT200600345A patent/GT200600345A/es unknown
- 2006-08-01 NZ NZ548863A patent/NZ548863A/en not_active IP Right Cessation
- 2006-08-01 SA SA06270254A patent/SA06270254B1/ar unknown
- 2006-08-01 SG SG200605172-6A patent/SG130111A1/en unknown
- 2006-08-02 TW TW095128301A patent/TWI327564B/zh not_active IP Right Cessation
- 2006-08-02 MX MXPA06008693A patent/MXPA06008693A/es active IP Right Grant
- 2006-08-02 MY MYPI20063734A patent/MY141306A/en unknown
- 2006-08-02 BR BRPI0603043-2A patent/BRPI0603043A/pt not_active Application Discontinuation
- 2006-08-02 EP EP06291252A patent/EP1752444A1/fr not_active Withdrawn
- 2006-08-02 EP EP08017459A patent/EP2008994A1/fr not_active Withdrawn
- 2006-08-02 AR ARP060103365A patent/AR057714A1/es unknown
- 2006-08-02 NO NO20063518A patent/NO20063518L/no not_active Application Discontinuation
- 2006-08-02 GE GEAP20069559A patent/GEP20094577B/en unknown
- 2006-08-02 EA EA200601271A patent/EA010867B1/ru not_active IP Right Cessation
- 2006-08-02 WO PCT/FR2006/001867 patent/WO2007015002A2/fr active Application Filing
- 2006-08-02 UA UAA200608687A patent/UA83718C2/ru unknown
- 2006-08-03 CN CNB2006101083948A patent/CN100445264C/zh not_active Expired - Fee Related
- 2006-08-03 AU AU2006203340A patent/AU2006203340B2/en not_active Ceased
- 2006-08-03 JP JP2006211621A patent/JP4580371B2/ja not_active Expired - Fee Related
- 2006-08-03 CA CA002555119A patent/CA2555119A1/fr not_active Abandoned
- 2006-08-03 ZA ZA200606455A patent/ZA200606455B/xx unknown
-
2007
- 2007-04-30 HK HK07104584.7A patent/HK1098129A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1098129A1 (en) | 2007-07-13 |
| EA200601271A1 (ru) | 2007-02-27 |
| EP2008994A1 (fr) | 2008-12-31 |
| MY141306A (en) | 2010-04-16 |
| MA28450B1 (fr) | 2007-03-01 |
| NO20063518L (no) | 2007-02-05 |
| CO5780132A1 (es) | 2007-07-31 |
| CN100445264C (zh) | 2008-12-24 |
| WO2007015002A2 (fr) | 2007-02-08 |
| WO2007015002A3 (fr) | 2007-04-12 |
| GEP20094577B (en) | 2009-01-12 |
| CN1907957A (zh) | 2007-02-07 |
| SG130111A1 (en) | 2007-03-20 |
| MXPA06008693A (es) | 2007-02-02 |
| AU2006203340B2 (en) | 2012-07-19 |
| FR2889522A1 (fr) | 2007-02-09 |
| EP1752444A1 (fr) | 2007-02-14 |
| BRPI0603043A (pt) | 2007-03-20 |
| NZ548863A (en) | 2008-03-28 |
| TW200736198A (en) | 2007-10-01 |
| CA2555119A1 (fr) | 2007-02-03 |
| ZA200606455B (en) | 2007-12-27 |
| FR2889522B1 (fr) | 2007-12-28 |
| UA83718C2 (ru) | 2008-08-11 |
| GT200600345A (es) | 2007-03-28 |
| JP4580371B2 (ja) | 2010-11-10 |
| SA06270254B1 (ar) | 2010-08-02 |
| JP2007051141A (ja) | 2007-03-01 |
| AU2006203340A1 (en) | 2007-02-22 |
| AR057714A1 (es) | 2007-12-12 |
| EA010867B1 (ru) | 2008-12-30 |
| PE20070242A1 (es) | 2007-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI327564B (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| TWI389873B (zh) | 阿戈美拉汀（ａｇｏｍｅｌａｔｉｎｅ）之新晶形iii，其製備方法及包含其之醫藥組合物 | |
| TWI359128B (en) | New crystalline form v of agomelatine, a process f | |
| TWI356051B (en) | New crystalline form vi of agomelatine, a process | |
| US7358395B2 (en) | Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| US7939566B2 (en) | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| US7910625B2 (en) | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| KR100904116B1 (ko) | 아고멜라틴의 ⅴ 결정형, 이의 제조 방법 및 이를 함유하는 약제 조성물 | |
| KR20070017020A (ko) | 아고멜라틴의 결정질 형태 ⅳ, 이의 제조 방법 및 이를함유하는 약제 조성물 | |
| KR20070017019A (ko) | 아고멜라틴의 결정질 형태 ⅲ, 이의 제조 방법 및 이를함유하는 약제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |